A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry

Table 1 Study schedule

	Screening/ Enrolment	CABG/ hospital discharge	1 month	Annual follow-up (1–5 years)
Inclusion and exclusion criteria	X
Informed consent	X
Patient characteristics/medical history	X
EuroSCORE II	X
Procedural data		X
EQ-5D-5 L	X			X
Health economic data derived			X	X
MACCE		X	X	X

MACCE Major adverse cardiac and cerebrovascular events (death, non-fatal myocardial infarction, repeat revascularisation, or stroke)

ISSN: 1749-8090